MedTrace Logo

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

NCT00206518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2020-07-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.

Conditions

Interventions

DRUG

Taxotere/Docetaxel

Taxotere

DRUG

Adriamycin/Cytoxan

Adriamycin/Cytoxan

DRUG

doxorubicin

AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Mothaffar Rimawi

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor Breast Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2016-10-31
Completion
2016-10-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206518 on ClinicalTrials.gov